Keratoconjunctivitis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Keratoconjunctivitis – Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis
- The report reviews pipeline therapeutics for Keratoconjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Keratoconjunctivitis therapeutics and enlists all their major and minor projects
- The report assesses Keratoconjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AB2 Bio LtdAbbVie Inc
Acahealth Pharma and Biotech Co Ltd
Actinobac Biomed Inc
AiCuris Anti-infective Cures AG
Alchemedicine Co Ltd
Alcon Inc
Aldeyra Therapeutics Inc
Allakos Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
Allosterix Ltd
Allysta Pharmaceuticals Inc
Aramis Biosciences Inc
Ascendia Pharmaceuticals Inc
Aviara Pharmaceuticals Inc
Avixgen Inc
AxeroVision Inc
Azura Ophthalmics Pty Ltd
Bessor Pharma LLC
Bio-Cancer Treatment International Ltd
BRIM Biotechnology Inc
BSIM Therapeutics SA
Cambium Medical Technologies LLC
CAMP Therapeutics Inc
Cell2Cure Aps
Changchun Jinsai Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
China Medical System Holdings Ltd
Chong Kun Dang Pharmaceutical Corp.
Chongqing Kerun Biopharm R & D Co Ltd
Chromocell Corp
Cloudbreak Therapeutics LLC
Curexsys GmbH
Daewoo Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
EncuraGen Co Ltd
Eye Bio Korea Co Ltd
GL Pharm Tech Corp
Glaukos Corp
Glia LLC
Grand Pharmaceutical Group Ltd
Grifols SA
H4Orphan Pharma
HanAll Biopharma Co Ltd
Hangzhou Yuansheng Biotechnology Co Ltd
Haplnscience Inc
Hbm Holdings Ltd
HLB Therapeutics Co Ltd
Huons Co Ltd
Huons Global Co Ltd
IACTA Pharmaceuticals Inc
Icure Pharmaceutical Inc
Ildong Pharmaceutical Co Ltd
IMD Farm Co Ltd
Incannex Healthcare Ltd
Inflamalps SA
Invirsa Inc
Invitrx Therapeutics Inc
Ipsen SA
IVIEW Therapeutics Inc
Japan Tobacco Inc
Jenivision Inc
Ji Xing Pharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Juvenescence UK Ltd
KALA BIO Inc
KinoPharma Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Laboratorios Salvat SA
Link Biologics Ltd
LTT Bio-Pharma Co Ltd
MC2 Therapeutics AS
Medicon Pharmaceuticals Inc
MediPrint Ophthalmics Inc
MeiraGTx Holdings Plc
Mimetogen Pharmaceuticals Inc
Mitotech SA
MyX Therapeutics Inc
NanoViricides Inc
Neuroptika Inc
Nexeos Bio
NicOx SA
NovaCell Technology Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocular Therapeutix Inc
Oculis Holding AG
Ocumension Therapeutics Co Ltd
OKYO Pharma Ltd
Ophrx Ltd
Ophtho-Therapeutics Inc
Optus Pharmaceutical Co Ltd
Palatin Technologies Inc
Panag Pharma Inc
PharmaResearch Co Ltd
Pinotbio Inc
Pleryon Therapeutics Ltd
Proteris Biotech Inc
Protokinetix Inc
Qilu Pharmaceutical Co Ltd
Quorum Innovations LLC
Redwood Pharma AB
Regenerate Therapeutics Inc
Regeneron Pharmaceuticals Inc
RegeneRx Biopharmaceuticals Inc
ReGenTree LLC
Rhizen Pharmaceuticals SA
RHNanopharmacuticals LLC
RiniSight Inc
Rudacure Co Ltd
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
Satellos Bioscience Inc
SCAI Therapeutics
Seinda Pharmaceutical Guangzhou Corp
Senelix Co Ltd
Senju Pharmaceutical Co Ltd
Serentrix LLC
SGN Nanopharma Inc
Shanghai Puyou Biomedical Co Ltd
SIFI Medtech Srl
SIFI SpA
Silk Technologies Ltd
Sinobioway Biomedical Co Ltd
Stowe Pharmaceuticals Inc
Stuart Therapeutics Inc
Sunhawk Vision Biotech Inc
Surface Ophthalmics Inc
Surrozen Inc
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
TagCyx Biotechnologies
Tarsier Pharma Ltd
TearSolutions Inc
Telios Pharma Inc
TelomEye Pharmaceuticals Corp
Tetra Bio-Pharma Inc
The United Laboratories International Holdings Ltd
Theialife Sciences Pvt Ltd
Theratocular Biotek Co Ltd
Theratome Bio Inc
University of Waterloo
Vanda Pharmaceuticals Inc
Viatris Inc
Viva Vision Biotech
Wuhan Yicheng Biotechnology Co Ltd
Xequel Bio Inc
Xiamen University
Yuyu Pharma Inc
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Zhejiang Raytone Biotechnology Co Ltd
Zhuhai Essex Bio-Pharmaceutical Co Ltd
Zhuhai United Laboratories Co Ltd